Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Migraine entities : Abbvie inc. save search
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: 0.0%
qulipta abbvie treatment for migraine
AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults
Published: 2023-08-17 (Crawled : 06:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.87%
H: 0.49%
C: -0.75%
aquipta abbvie approval treatment migraine
AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine
Published: 2023-06-23 (Crawled : 12:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.08%
H: 1.01%
C: -1.01%
abbvie chmp positive treatment migraine
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting
Published: 2023-04-21 (Crawled : 05:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.53%
H: 0.37%
C: -0.11%
qulipta abbvie treatment meeting trial migraine results
U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
Published: 2023-04-18 (Crawled : 08:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.11%
H: 0.14%
C: -0.88%
qulipta fda migraine
U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
Published: 2023-04-17 (Crawled : 00:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.11%
H: 0.14%
C: -0.88%
qulipta fda migraine
Global Acute Migraine Drugs Market Report 2023: Markey Insights and Forecasts 2018-2022 & 2023-2028 - Competitive Developments, Strategies, Mergers and Acquisitions and New Product Developments
Published: 2023-03-10 (Crawled : 20:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
| Email alert
Add to watchlist
global report acquisitions migraine market
AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress
Published: 2022-12-06 (Crawled : 08:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.05%
H: 0.22%
C: -0.19%
migraine
Migraine drugs market in Latin America 2023-2027: 5-Year (2017-2021) historic industry size and analysis of 15 vendors and 7 countries - Technavio
Published: 2022-12-06 (Crawled : 02:00) - prnewswire.com
ENDPQ | News | $0.0007 -50.0% 1K
|
n/a
|
| O: -2.59%
H: 4.21%
C: 2.0%
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 2.04%
H: 8.0%
C: 7.71%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.74%
H: 8.46%
C: 8.46%
IGXT | $0.1699 -19.77% 44K
|
Manufacturing
|
| O: -6.33%
H: 9.38%
C: 7.52%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: -1.19%
H: 14.39%
C: 9.15%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.05%
H: 0.22%
C: -0.19%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.33%
H: 0.56%
C: -0.89%
america migraine market
The Global Migraine Drugs Market is expected to grow by $1 bn during 2022-2026, accelerating at a CAGR of 5.74% during the forecast period
Published: 2022-11-21 (Crawled : 16:00) - prnewswire.com
ENDPQ | News | $0.0007 -50.0% 1K
|
n/a
|
| O: -1.63%
H: 3.73%
C: 3.63%
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: 3.09%
H: 0.0%
C: -1.59%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.74%
H: 0.89%
C: 0.53%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 2.04%
H: 0.06%
C: -0.36%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.27%
H: 2.08%
C: 1.1%
ABT | News | $107.59 0.49% -0.09% 3.8M
|
Health Technology
|
| O: -0.13%
H: 1.13%
C: 0.14%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.68%
H: 0.35%
C: -0.12%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.63%
H: 0.87%
C: -0.32%
global expected migraine market
AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine
Published: 2022-07-18 (Crawled : 07:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
treatment ema application migraine authorization
Migraine Therapeutics Market Report 2021: Featuring Major Vendors including AbbVie Inc., Amgen Inc. & Eli Lilly and Co.- Technavio
Published: 2022-07-13 (Crawled : 11:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: -0.1%
H: 0.05%
C: -1.41%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: -1.62%
H: 0.83%
C: 0.37%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.98%
H: 1.2%
C: 0.1%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.24%
H: 0.97%
C: 0.29%
report therapeutics migraine market
AbbVie Seeks New Indication for Migraine Drug Qulipta, Drops Deal with Morphic
Published: 2022-06-22 (Crawled : 16:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 2.73%
H: 4.44%
C: 2.67%
drug deal migraine
AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine
Published: 2022-06-21 (Crawled : 14:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 1.48%
H: 0.0%
C: 0.0%
treatment fda expansion drug label application migraine
AbbVie Prepares to Seek Supplemental Approval for Migraine Treatment
Published: 2022-03-10 (Crawled : 19:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
treatment approval migraine
AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine
Published: 2022-03-10 (Crawled : 13:30) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
treatment pos migraine positive phase 3
New Relief for Migraine Sufferers as FDA Approves AbbVie's Atogepant
Published: 2021-09-29 (Crawled : 16:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.48%
H: 1.6%
C: 0.92%
fda migraine approval fda approval
FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine
Published: 2021-09-28 (Crawled : 00:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.48%
H: 1.6%
C: 0.92%
treatment fda migraine fda approval
AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress
Published: 2021-09-08 (Crawled : 15:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.89%
H: 2.63%
C: 2.13%
migraine
New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine
Published: 2021-08-18 (Crawled : 22:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.92%
H: 2.37%
C: 1.48%
treatment migraine results
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.